<a href="https://www.fiercebiotech.com/biotech/denmarks-leo-pharma-pays-50m-replay-and-its-preclinical-skin-disease-gene-therapy" hreflang="en">Leo Pharma pays $50M for Replay and its preclinical skin disease gene therapy</a>
Leo Pharma has acquired U.S. biotech company Replay for $50 million to gain access to its preclinical gene therapy platform targeting rare genetic skin diseases, particularly a treatment for dystrophic epidermolysis bullosa. The acquisition aligns with Leo's strategy to enhance its dermatology portfolio and leverage Replay's innovative HSV delivery technology.
Leo Pharma's acquisition of Replay for $50 million highlights the strategic move towards leveraging next-generation gene therapy platforms to address rare genetic dermatological conditions. This deal underscores the importance of investing in technologies with high-payload delivery vectors such as HSV, which are particularly suited for delivering large genes in skin disease treatments. For professionals tracking healthtech and biotech investments, this acquisition emphasizes the growing value placed on gene therapy solutions that can be integrated with established dermatological expertise for significant market impact.